Nanobiotix SA (NANO) EUR0.03

Sell:€7.93Buy:€8.09€0.42 (5.02%)

Prices delayed by at least 15 minutes
Sell:€7.93
Buy:€8.09
Change:€0.42 (5.02%)
Prices delayed by at least 15 minutes
Sell:€7.93
Buy:€8.09
Change:€0.42 (5.02%)
Prices delayed by at least 15 minutes

Company Information

About this company

Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.

Key people

Laurent Levy
Chief Executive Officer
Bart Van Rhijn
Chief Financial & Business Officer
Anne-Juliette Hermant
Chief Human Resources Officer
Craig West
Senior Vice President - Investor Relations
Anne-Sophie Lariviere
Vice President - Strategy & Operational Excellence
Brandon Owens
Vice President - Strategic Marketing and Corporate Communications
Louis Kayitalire
Chief Medical Officer
Gary M. Phillips
Independent Chairman of the Board
Anne-Marie Graffin
Independent Vice Chairwoman of the of the Board
Margaret Liu
Director
Anat Naschitz
Director
Alain Herrera
Independent Director
Click to see more

Key facts

  • EPIC
    NANO
  • Location
    France
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    FR0011341205
  • Market cap
    €401.28m
  • Employees
    108
  • Shares in issue
    47.43m
  • Exchange
    Euronext Paris
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.